vs
HALOZYME THERAPEUTICS, INC.（HALO）与泰尼特医疗（HCSG）财务数据对比。点击上方公司名可切换其他公司
泰尼特医疗的季度营收约是HALOZYME THERAPEUTICS, INC.的1.0倍（$466.7M vs $451.8M），HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs 6.6%），HALOZYME THERAPEUTICS, INC.自由现金流更多（$217.6M vs $16.0M），过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs 5.0%）
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
泰尼特医疗集团是一家总部位于达拉斯的美国上市营利性跨国医疗服务企业，旗下通过品牌、子公司、合资企业及合作项目（包括联合外科合作伙伴国际USPI），运营着65家医院与超450家医疗机构，此外还经营康尼弗医疗解决方案，为医疗系统及其他客户提供医疗配套服务支持。
HALO vs HCSG — 直观对比
营收规模更大
HCSG
是对方的1.0倍
$451.8M
营收增速更快
HALO
高出45.0%
6.6%
自由现金流更多
HALO
多$201.6M
$16.0M
两年增速更快
HALO
近两年复合增速
5.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $451.8M | $466.7M |
| 净利润 | $-141.6M | — |
| 毛利率 | 82.6% | 15.4% |
| 营业利润率 | -20.6% | 6.1% |
| 净利率 | -31.3% | — |
| 营收同比 | 51.6% | 6.6% |
| 净利润同比 | -203.3% | — |
| 每股收益（稀释后） | $-1.13 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HALOHCSG
| Q4 25 | $451.8M | $466.7M | ||
| Q3 25 | $354.3M | $464.3M | ||
| Q2 25 | $325.7M | $458.5M | ||
| Q1 25 | $264.9M | $447.7M | ||
| Q4 24 | $298.0M | $437.8M | ||
| Q3 24 | $290.1M | $428.1M | ||
| Q2 24 | $231.4M | $426.3M | ||
| Q1 24 | $195.9M | $423.4M |
净利润HALOHCSG
| Q4 25 | $-141.6M | — | ||
| Q3 25 | $175.2M | $43.0M | ||
| Q2 25 | $165.2M | $-32.4M | ||
| Q1 25 | $118.1M | $17.2M | ||
| Q4 24 | $137.0M | — | ||
| Q3 24 | $137.0M | $14.0M | ||
| Q2 24 | $93.2M | $-1.8M | ||
| Q1 24 | $76.8M | $15.3M |
毛利率HALOHCSG
| Q4 25 | 82.6% | 15.4% | ||
| Q3 25 | 84.4% | 20.8% | ||
| Q2 25 | 85.8% | 0.6% | ||
| Q1 25 | 81.7% | 15.2% | ||
| Q4 24 | 85.9% | 13.4% | ||
| Q3 24 | 83.0% | 14.8% | ||
| Q2 24 | 82.9% | 9.7% | ||
| Q1 24 | 85.5% | 15.2% |
营业利润率HALOHCSG
| Q4 25 | -20.6% | 6.1% | ||
| Q3 25 | 61.5% | 12.3% | ||
| Q2 25 | 62.2% | -9.1% | ||
| Q1 25 | 53.4% | 5.3% | ||
| Q4 24 | 58.9% | 3.4% | ||
| Q3 24 | 56.3% | 4.4% | ||
| Q2 24 | 50.7% | -0.5% | ||
| Q1 24 | 48.8% | 5.0% |
净利率HALOHCSG
| Q4 25 | -31.3% | — | ||
| Q3 25 | 49.5% | 9.3% | ||
| Q2 25 | 50.7% | -7.1% | ||
| Q1 25 | 44.6% | 3.8% | ||
| Q4 24 | 46.0% | — | ||
| Q3 24 | 47.2% | 3.3% | ||
| Q2 24 | 40.3% | -0.4% | ||
| Q1 24 | 39.2% | 3.6% |
每股收益（稀释后）HALOHCSG
| Q4 25 | $-1.13 | $0.43 | ||
| Q3 25 | $1.43 | $0.59 | ||
| Q2 25 | $1.33 | $-0.44 | ||
| Q1 25 | $0.93 | $0.23 | ||
| Q4 24 | $1.06 | $0.15 | ||
| Q3 24 | $1.05 | $0.19 | ||
| Q2 24 | $0.72 | $-0.02 | ||
| Q1 24 | $0.60 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.8M | $168.0M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $48.8M | $510.2M |
| 总资产 | $2.5B | $794.3M |
| 负债/权益比越低杠杆越低 | 43.89× | — |
8季度趋势，按日历期对齐
现金及短期投资HALOHCSG
| Q4 25 | $133.8M | $168.0M | ||
| Q3 25 | $419.7M | $177.5M | ||
| Q2 25 | $61.9M | $134.5M | ||
| Q1 25 | $176.3M | $114.8M | ||
| Q4 24 | $115.8M | $107.3M | ||
| Q3 24 | $154.3M | $103.8M | ||
| Q2 24 | $187.9M | $105.6M | ||
| Q1 24 | $164.6M | $104.9M |
总债务HALOHCSG
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
股东权益HALOHCSG
| Q4 25 | $48.8M | $510.2M | ||
| Q3 25 | $503.9M | $496.0M | ||
| Q2 25 | $332.7M | $477.0M | ||
| Q1 25 | $482.3M | $514.2M | ||
| Q4 24 | $363.8M | $499.9M | ||
| Q3 24 | $452.7M | $488.7M | ||
| Q2 24 | $289.4M | $471.4M | ||
| Q1 24 | $177.8M | $474.6M |
总资产HALOHCSG
| Q4 25 | $2.5B | $794.3M | ||
| Q3 25 | $2.2B | $804.3M | ||
| Q2 25 | $2.1B | $802.2M | ||
| Q1 25 | $2.2B | $823.0M | ||
| Q4 24 | $2.1B | $802.8M | ||
| Q3 24 | $2.1B | $805.8M | ||
| Q2 24 | $2.0B | $799.7M | ||
| Q1 24 | $1.8B | $803.9M |
负债/权益比HALOHCSG
| Q4 25 | 43.89× | — | ||
| Q3 25 | 3.00× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | — | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — | ||
| Q1 24 | 8.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $219.0M | $17.4M |
| 自由现金流经营现金流 - 资本支出 | $217.6M | $16.0M |
| 自由现金流率自由现金流/营收 | 48.2% | 3.4% |
| 资本支出强度资本支出/营收 | 0.3% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $644.6M | $139.2M |
8季度趋势，按日历期对齐
经营现金流HALOHCSG
| Q4 25 | $219.0M | $17.4M | ||
| Q3 25 | $178.6M | $71.3M | ||
| Q2 25 | $99.7M | $28.8M | ||
| Q1 25 | $154.2M | $27.5M | ||
| Q4 24 | $178.5M | $36.2M | ||
| Q3 24 | $115.4M | $4.3M | ||
| Q2 24 | $55.8M | $16.3M | ||
| Q1 24 | $129.4M | $-26.0M |
自由现金流HALOHCSG
| Q4 25 | $217.6M | $16.0M | ||
| Q3 25 | $175.6M | $70.0M | ||
| Q2 25 | $98.1M | $27.4M | ||
| Q1 25 | $153.3M | $25.8M | ||
| Q4 24 | $175.4M | $34.8M | ||
| Q3 24 | $113.9M | $2.9M | ||
| Q2 24 | $53.2M | $15.0M | ||
| Q1 24 | $125.9M | $-28.2M |
自由现金流率HALOHCSG
| Q4 25 | 48.2% | 3.4% | ||
| Q3 25 | 49.6% | 15.1% | ||
| Q2 25 | 30.1% | 6.0% | ||
| Q1 25 | 57.9% | 5.8% | ||
| Q4 24 | 58.9% | 7.9% | ||
| Q3 24 | 39.3% | 0.7% | ||
| Q2 24 | 23.0% | 3.5% | ||
| Q1 24 | 64.3% | -6.7% |
资本支出强度HALOHCSG
| Q4 25 | 0.3% | 0.3% | ||
| Q3 25 | 0.9% | 0.3% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | 0.4% | 0.4% | ||
| Q4 24 | 1.0% | 0.3% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 1.1% | 0.3% | ||
| Q1 24 | 1.8% | 0.5% |
现金转化率HALOHCSG
| Q4 25 | — | — | ||
| Q3 25 | 1.02× | 1.66× | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 1.31× | 1.60× | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.84× | 0.31× | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 1.68× | -1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
HCSG
| Dietary Services | $255.9M | 55% |
| Other | $210.8M | 45% |
